[go: up one dir, main page]

HUP9802206A1 - Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához - Google Patents

Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához

Info

Publication number
HUP9802206A1
HUP9802206A1 HU9802206A HUP9802206A HUP9802206A1 HU P9802206 A1 HUP9802206 A1 HU P9802206A1 HU 9802206 A HU9802206 A HU 9802206A HU P9802206 A HUP9802206 A HU P9802206A HU P9802206 A1 HUP9802206 A1 HU P9802206A1
Authority
HU
Hungary
Prior art keywords
intravenous
thaidomid
composition
immunological diseases
treating immunological
Prior art date
Application number
HU9802206A
Other languages
English (en)
Inventor
Sven Björkman
Tommy Eriksson
Peter Höglund
Original Assignee
Grünenthal GmbH.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7844650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9802206(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH. filed Critical Grünenthal GmbH.
Publication of HU9802206D0 publication Critical patent/HU9802206D0/hu
Publication of HUP9802206A1 publication Critical patent/HUP9802206A1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

NCS = (57) A találmány szerinti vizes thalidomid-oldat alkalmasthalidomid immunológiai megbetegedéseknél történő parenterális -különösen intravénás - adagolására. A találmány továbbá a fentimegfelelő thalidomid-oldat előállítására vonatkozik. Ó
HU9802206A 1997-10-06 1998-10-05 Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához HUP9802206A1 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19743968A DE19743968C2 (de) 1997-10-06 1997-10-06 Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen

Publications (2)

Publication Number Publication Date
HU9802206D0 HU9802206D0 (en) 1998-11-30
HUP9802206A1 true HUP9802206A1 (hu) 2000-12-28

Family

ID=7844650

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802206A HUP9802206A1 (hu) 1997-10-06 1998-10-05 Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához

Country Status (13)

Country Link
US (1) US6124322A (hu)
EP (1) EP0908176B1 (hu)
JP (1) JPH11189534A (hu)
AT (1) ATE229323T1 (hu)
AU (1) AU732634B2 (hu)
CA (1) CA2248838A1 (hu)
DE (2) DE19743968C2 (hu)
DK (1) DK0908176T3 (hu)
ES (1) ES2189059T3 (hu)
HU (1) HUP9802206A1 (hu)
NZ (1) NZ331563A (hu)
PT (1) PT908176E (hu)
SI (1) SI0908176T1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
DE50001522D1 (de) 1999-03-31 2003-04-30 Gruenenthal Gmbh Stabile wässrige Lösung von 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
AU5448300A (en) * 1999-05-27 2000-12-18 Rockefeller University, The Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
GB2371767A (en) * 2001-02-02 2002-08-07 Labman Automation Ltd Dissolving materials by application of agitation and ultrasound
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
JP4943845B2 (ja) 2003-09-17 2012-05-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ サリドマイド類似体
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
MX2021012901A (es) * 2019-04-22 2021-11-17 Starton Therapeutics Inc Metodo de administracion continua de lenalidomida y otros agentes inmunomoduladores.
CN117098531A (zh) 2021-01-08 2023-11-21 斯塔顿治疗公司 用于肠胃外使用的免疫调节酰亚胺化合物的稳定溶液

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
AU661299B2 (en) * 1991-04-17 1995-07-20 Grunenthal Gmbh New thalidomide derivatives, method of manufacture and use thereof in medicaments
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Also Published As

Publication number Publication date
PT908176E (pt) 2003-04-30
DE59806612D1 (de) 2003-01-23
ATE229323T1 (de) 2002-12-15
DE19743968A1 (de) 1999-04-15
EP0908176A1 (de) 1999-04-14
JPH11189534A (ja) 1999-07-13
SI0908176T1 (en) 2003-04-30
AU8792598A (en) 1999-04-22
US6124322A (en) 2000-09-26
HK1018591A1 (en) 1999-12-30
EP0908176B1 (de) 2002-12-11
DE19743968C2 (de) 2002-07-11
DK0908176T3 (da) 2003-01-06
CA2248838A1 (en) 1999-04-06
NZ331563A (en) 1999-01-28
ES2189059T3 (es) 2003-07-01
HU9802206D0 (en) 1998-11-30
AU732634B2 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
FI931226A7 (fi) Hitaasti vapautuvia koostumuksia periodontaalisen sairauden hoitamisek si
IT1211852B (it) Composizione di collirio isotonico umettante
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
NO178378C (no) Fremgangsmåte for fremstilling av peroksidiske perfluorpolyetere
PT86132A (en) Process for the preparation of detergent compositions containing agents
YU56995A (sh) Soli derivata indola
IT1232889B (it) Composizioni e procedimento per il trattamento ammorbidente di tessuti
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
IT1223773B (it) Composizioni vulcanizzabili di organopolisilossani
HU912486D0 (en) Process for producing ethers and thioethers of piperidyl
FI884720A7 (fi) Varjoaineina käytettäviä koostumuksia
FR2651435B1 (hu)
FR2599752B1 (fr) Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
NO891894D0 (no) Fremgangsmaate for fremstilling av antikoagulerende peptidalkoholer.
IT8420682A1 (it) "Procedimento per il trattamento di articoli di maglieria"
EP0420116A3 (en) Novel substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
ATE118209T1 (de) Pyridin-3-percarboxylsäure monopersulfat.
ATE43342T1 (de) Verfahren zur herstellung von hydrogeno- oder halogenosilanen.
IT8621734A0 (it) Processo per la preparazione dell'alfa-n-[(ipoxatin-9-il)pentilossicarbonil-]arginina
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen
FR2559157B1 (fr) Nouvel hexapeptide, son procede d'obtention et les compositions pharmaceutiques qui le contiennent
PT88651A (pt) Processo de preparacao de 1(2h)-ftalazinonas uteis como agentes citoprotectores

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees